SEC Company Response from EAGLE PHARMACEUTICALS, INC. (EGRX) (CIK 0000827871) — Oct 17, 2022
EAGLE PHARMACEUTICALS, INC. (EGRX) (CIK 0000827871)
Date: Oct. 17, 2022 · CIK: 0000827871 · Accession: 0001104659-22-109317
AI Filing Summary & Sentiment
File numbers found in text: 333-267827
Letter
Eagle Pharmaceuticals, Inc.
50 Tice Boulevard, Suite
Woodcliff Lake, New Jersey
October 17, 2022
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn:
Alan Campbell
Re:
Eagle Pharmaceuticals, Inc.
Registration Statement on Form S-3 (File No. 333-267827)
Request for Acceleration of Effective Date
Mr. Campbell:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-267827) (the “Registration Statement”) to become effective on October 19, 2022, at 4:00 p.m. Eastern Time, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Sarah Sellers of Cooley LLP, counsel to the Registrant, at (212) 479-6370, or in her absence, Marc Recht at (617) 937-2316.
[Signature page follows]
Very truly yours,
Eagle Pharmaceuticals, Inc.
Show Raw Text
CORRESP
1
filename1.htm
Eagle
Pharmaceuticals, Inc.
50 Tice Boulevard, Suite
315
Woodcliff Lake, New Jersey
07677
October 17, 2022
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn:
Alan Campbell
Re:
Eagle Pharmaceuticals, Inc.
Registration Statement on Form S-3 (File No. 333-267827)
Request for Acceleration of Effective Date
Mr. Campbell:
In accordance with Rule 461 under the Securities
Act of 1933, as amended, the undersigned registrant (the “Registrant”) hereby requests that the Securities and
Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-267827) (the
“Registration Statement”) to become effective on October 19, 2022, at 4:00 p.m. Eastern Time, or as soon thereafter
as is practicable.
Once the Registration Statement has been declared effective, please
orally confirm that event with Sarah Sellers of Cooley LLP, counsel to the Registrant, at (212) 479-6370, or in her absence, Marc Recht
at (617) 937-2316.
[Signature page follows]
Very truly yours,
Eagle Pharmaceuticals, Inc.
By:
/s/ Brian Cahill
Brian Cahill
Chief Financial Officer
cc:
Ryan Debski, Eagle Pharmaceuticals, Inc.
Brian Cahill, Eagle Pharmaceuticals, Inc.
Marc Recht, Cooley LLP
Sarah Sellers, Cooley LLP
Signature Page to Company
Acceleration Request – S-3